Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia
Authors:
- Susanna KharitSKSusanna Kharit
- Leila Namazova-BaranovaLNLeila Namazova-Baranova
- Asmik AsatryanAAAsmik Asatryan
- Mayya BenashviliMBMayya Benashvili
- Elmira TkhostovaETElmira Tkhostova
- Chiranjiwi BhusalCBChiranjiwi Bhusal
- Ashwani Kumar AroraAAAshwani Kumar Arora
- 20 June 2014
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (8) , 2471-2481
Abstract
Neisseria meningitidis is the leading cause of bacterial invasive infections in people aged <15 years in the Russian Federation. The aim of this phase III, multicenter, open-label study was to assess the immunogenicity and safety of the quadrivalent meningococcal CRM197-conjugate vaccine MenACWY when administered to healthy Russian subjects aged 2 years and above. A total of 197 subjects were immunized with a single dose of the vaccine, and serogroup-specific serum bactericidal activity was measured pre and 1-month post-vaccination with human complement (hSBA) serum titers. Regardless of baseline serostatus, 1 month after a single dose of MenACWY-CRM197 85% (95%CI, 79–90%) of subjects showed serologic response against serogroup A, 74% (67–80%) against serogroup C, 60% (53–67%) against serogroup W, and 83% (77–88%) against serogroup Y. The percentage of subjects with hSBA titers ≥ 1:8 1 month after vaccination was 89% (83–93%) against serogroup A, 84% (78–89%) against serogroup C, 97% (93–99%) against sero...Keywords
This publication has 36 references indexed in Scilit:
- Description and Nomenclature of Neisseria meningitidis Capsule LocusEmerging Infectious Diseases, 2013
- Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in AdolescentsThe Pediatric Infectious Disease Journal, 2013
- Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in InfantsThe Pediatric Infectious Disease Journal, 2012
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of ageVaccine, 2010
- Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young AdultsClinical and Vaccine Immunology, 2010
- Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlersEuropean Journal of Clinical Microbiology & Infectious Diseases, 2009
- Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, MenactraClinical and Vaccine Immunology, 2009
- Neisseria meningitidis: an overview of the carriage stateJournal of Medical Microbiology, 2004
- Complications and sequelae of meningococcalinfections in childrenThe Journal of Pediatrics, 1981